1-20 of 27
Keywords: Etoposide
Close
Sort by
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2011) 80 (5-6): 330–332.
Published Online: 27 July 2011
... II trials combining ifosfamide, carboplatin and etoposide chemotherapy (ICE) showed favorable results. We therefore applied the ICE protocol to 13 patients (10 GBM, 3 anaplastic astrocytomas). Partial or complete remissions were not observed. None of the 13 patients survived progression-free for 6...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1996) 53 (4): 327–333.
Published Online: 30 June 2009
...Yoshinobu Ohsaki; Sakae Ishida; Toshiaki Fujikane; Kenjiro Kikuchi The effect of pentoxifylline (PENT) on the sensitivity of two human lung adenocarcinoma cell lines, PC-9 and PC-14, to cisplatin (CDDP) and etoposide (ET) was studied. PENT at 0.5 and 1 m M enhanced the cytotoxicity of CDDP and ET...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1996) 53 (6): 482–487.
Published Online: 30 June 2009
...J.S. Nel; Carta I. Falkson Forty-one patients with acute non-lymphoblastic leukemia were treated between March 1990 and November 1993 with mitoxantrone, cytarabine, etoposide and granulocyte-macrophage-colony-stimulating factor (GM-CSF) started on day 1. This was given as induction, consolidation...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1997) 54 (1): 48–54.
Published Online: 30 June 2009
... in 6 of 15 cell lines. Five of 8 ovarian cancer cell lines but none of 4 choriocarcinoma cell lines expressed the Fas Ag. In drug-resistant cell lines derived from one of the Fas-positive cells, its expression was not lost after development of resistance to cisplatin, SN-38 or etoposide, but its...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1994) 51 (4): 352–355.
Published Online: 30 June 2009
...A. Lluch; P. Azagra; A. Cervantes; M. Muñoz; V. Alberola; P. Santabarbara; J. García-Conde Twenty-two patients with metastatic breast carcinoma were treated with a combination of cisplatin (100 mg/m 2 i.v. day 1) and etoposide (100 mg/m 2 i.v. days 1-3). Eligible patients had measurable disease...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1990) 47 (2): 112–114.
Published Online: 26 June 2009
...Magnus Björkholm; Johanna Björnsdottir; Leif Stenke; Gunnar Grimfors In a phase I/II study mitoxantrone and etoposide, in combination with cytarabine, were given to 26 patients with refractory, relapsed, and previously untreated acute nonlymphocytic leukemia. Therapy consisted of mitoxantrone 12 mg...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1991) 48 (5): 353–355.
Published Online: 26 June 2009
... with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3 ± 7%); 9 patients had partial response (31 ± 17%); 5 patients (17±14%) were considered stable (S) and 14 (48 ± 18%) were classified as progressive. The average survival time...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1992) 49 (2): 104–107.
Published Online: 26 June 2009
...W.R. Bezwoda; L. Seymour; S. Ariad High-dose etoposide (1,500-2,500 mg/m 2 ) was used for the treatment of 23 previously treated patients with advanced breast cancer. Six of 23 (26%) showed objective regression with a median duration of response of 5 months. Responses were seen at all sites apart...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1992) 49 (Suppl. 1): 11–18.
Published Online: 26 June 2009
...James F. Bishop Carboplatin/etoposide is an active combination in small cell lung cancer. In phase II studies, it produces results that appear equivalent to cisplatin/etopo-side, but it has not been compared in a randomized study. It has a better toxicity profile than cisplatin/etoposide when...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1992) 49 (Suppl. 1): 43–50.
Published Online: 26 June 2009
... as clearly superior, the highest 1-year survival rate (25%) in ECOG trials was observed in EP(etoposide/ cisplatin)-treated patients. Subsequently, a randomized trial in which EP was compared to etoposide/carboplatin revealed no significant differences in survival or response rate, and toxicity was slightly...